Market Place
Sourcing Support
Recce Receives Approval for Ph 3 Diabetic Foot Infection Trial
10 Dec 2024 //
GLOBENEWSWIRE
Recce Pharma Granted Australia Patent for RECCE® Anti-Infectives
27 Nov 2024 //
GLOBENEWSWIRE
Recce Pharma Gets Ethics Approval for Phase 3 Diabetic Foot Trial
12 Nov 2024 //
GLOBENEWSWIRE
Recce Pharmaceuticals Advances Phase II Dosing for Skin Infections
06 Nov 2024 //
GLOBENEWSWIRE
Recce Pharmaceuticals Announces Phase II ABSSSI Trial Data
31 Oct 2024 //
GLOBENEWSWIRE
Recce Recruit in Ph II Trial for Acute Bacterial Skin Infections
10 Oct 2024 //
GLOBENEWSWIRE
Recce Pharmaceuticals Announces Successful Completion of Share Purchase Plan
06 Aug 2024 //
GLOBENEWSWIRE
Recce Pharma Receives $2M DoD Grant For RECCE 327 Gel
16 Jul 2024 //
GLOBENEWSWIRE
Recce Reports Positive Data Against Acinetobacter Baumannii Pathogen
10 Jul 2024 //
GLOBENEWSWIRE
Recce Reports Positive Data From UTI/Urosepsis Trial Of RECCE 327
01 Jul 2024 //
GLOBENEWSWIRE
Recce Pharmaceuticals Broadens RECCE® 327 Gel Trials with Ethics Approval
25 Jun 2024 //
GLOBENEWSWIRE
Recce Adds RECCE® 327 To WHO’s List Of Antibacterial Products In Development
20 Jun 2024 //
GLOBENEWSWIRE
Recce Completes Dosing In Phase I II UTI Urosepsis Trial
12 Jun 2024 //
GLOBENEWSWIRE
Recce Doses First In Next UTI/Urosepsis Rapid Infusion Cohort
17 May 2024 //
GLOBENEWSWIRE
Recce Pharma Reports Positive Preclinical RECCE 327 Data In Lung Infection
13 May 2024 //
GLOBENEWSWIRE
Recce`s receives 2 patents in China for its RECCE 327, RECCE 529 anti-infectives
09 May 2024 //
PHARMABIZ
Recce Pharmaceuticals Granted New Patent in China for RECCE® Anti-Infectives
08 May 2024 //
GLOBENEWSWIRE
Recce Safety Committee Clears 4,000mg Dose in Ph1/2 UTI/Urosepsis
30 Apr 2024 //
GLOBENEWSWIRE
Recce Completes 5,000 GMP Doses of RECCE® 327 Weekly
17 Apr 2024 //
GLOBENEWSWIRE
Recce Pharmaceuticals Completes R327 Batch Under GMP
17 Apr 2024 //
BIOSPACE
Recce Pharmaceuticals Provides Business Update
10 Apr 2024 //
GLOBENEWSWIRE
Recce Pharma Chosen by UK Govt Innovation Agency for AMR Mission 2024
09 Apr 2024 //
GLOBENEWSWIRE
Recce Pharmaceuticals Granted New Patent in Israel for RECCE® Anti-Infectives
04 Apr 2024 //
GLOBENEWSWIRE
Recce Announces RECCE® Trademark Registered in Canada, Global IP Portfolio
22 Mar 2024 //
GLOBENEWSWIRE
Recce Completes Dosing Cohort in Phase I/II Trial of RECCE® 327
19 Mar 2024 //
GLOBENEWSWIRE
Recce Pharmaceuticals Doses Next Cohort in Phase I/II Trial of RECCE® 327
14 Mar 2024 //
GLOBENEWSWIRE
Recce Pharmaceuticals to Present at the ASCPT 2024 Annual Meeting
13 Mar 2024 //
GLOBENEWSWIRE
Recce Receives AUD $11.17 Million Research and Development (R&D) Advance
12 Mar 2024 //
GLOBENEWSWIRE
Recce Continues Strategic Partnership with Murdoch Children™s Research Institute
29 Feb 2024 //
GLOBENEWSWIRE
Recce Pharmaceuticals Announces Expansion of Phase I/II Trial of RECCE® 327
27 Feb 2024 //
GLOBENEWSWIRE
Recce partners Indonesia`s Etana Biotech
08 Feb 2024 //
BIOSPECTRUM ASIA
Recce Establishes Partnership in South-East Asia to Accelerate Clinical Program
07 Feb 2024 //
GLOBENEWSWIRE
Recce Pharmaceuticals Reports Positive Phase I/II Trial Results of RECCE® 327
23 Jan 2024 //
GLOBENEWSWIRE
Recce Pharmaceuticals Awarded AusIndustry Advanced Overseas Finding
19 Dec 2023 //
GLOBENEWSWIRE
Recce Reports Positive Preclinical Data of RECCE® 327 Against Gonorrhea
18 Dec 2023 //
GLOBENEWSWIRE
Recce Pharmaceuticals Granted New Patent in Canada for RECCE® Anti-Infectives
27 Nov 2023 //
GLOBENEWSWIRE
Recce Completes Dosing First Subjects in a Phase I/II Trial of RECCE® 327
09 Nov 2023 //
GLOBENEWSWIRE
Recce Announces Committee Approves Infusion Rate in Ph I/II Trial of RECCE 327
25 Oct 2023 //
GLOBENEWSWIRE
Recce Pharmaceuticals Announces Results of Entitlement Offer
03 Oct 2023 //
GLOBENEWSWIRE
Recce Completes Dosing in Phase I/II Clinical Trial of RECCE® 327
26 Sep 2023 //
GLOBENEWSWIRE
Recce Secures $8M Placement and Launches $3M Entitlement Offer to Shareholders
13 Sep 2023 //
GLOBENEWSWIRE
Recce Pharmaceuticals Announces RECCE Trademark Registered in Vietnam
07 Sep 2023 //
GLOBENEWSWIRE
Recce Provides Positive Update on Patients Treated Under Special Access Scheme
01 Sep 2023 //
GLOBENEWSWIRE
Recce Announces Safety Committee Approves Next Dose of RECCE 327
29 Aug 2023 //
GLOBENEWSWIRE
Recce receives green light for higher dose in rapid infusion ph I/II UTI trial
28 Aug 2023 //
THEMARKETHERALD
Safety Committee Approves Next Dose of 3,000mg in Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial
28 Aug 2023 //
PRESS RELEASE
Recce Pharmaceuticals Completes Stage 1 Data Analysis of Phase I/II Trial
23 Aug 2023 //
GLOBENEWSWIRE
Recce Provides Positive Update on Patients Treated with RECCE® 327
10 Aug 2023 //
GLOBENEWSWIRE
Recce Granted New Anti-Viral Patent in Australia for RECCE® Anti-Infectives
04 Aug 2023 //
GLOBENEWSWIRE
Recce Receives Canadian Scientific Research and Experimental Development Rebate
02 Aug 2023 //
GLOBENEWSWIRE
Recce Completes First Cohort Dosing of Phase l/ll UTI Rapid Infusion Trial
01 Aug 2023 //
GLOBENEWSWIRE
Recce Pharmaceuticals to Present at the 2023 MHSRS
31 Jul 2023 //
GLOBENEWSWIRE
Recce Doses Subjects in Rapid Infusion Phase I/II UTI Trial of RECCE® 327
26 Jul 2023 //
GLOBENEWSWIRE
Recce Pharma Achieves Positive Phase I Trial Data of RECCE 327
20 Jul 2023 //
GLOBENEWSWIRE
Recce Pharma Receives A$801,604 Research and Development (R&D) Rebate Advance
13 Jul 2023 //
GLOBENEWSWIRE
Recce Announces First Cohort Dosed in RECCE 327 Rapid Infusion Ph I/II UTI Trial
11 Jul 2023 //
GLOBENEWSWIRE
Recce Pharmaceuticals Announces Change of Director Interest Notices
28 Jun 2023 //
GLOBENEWSWIRE
Recce to be Granted New Anti-Viral Patent in Australia for RECCE Anti-Infectives
11 Apr 2023 //
GLOBENEWSWIRE
Recce Receives Further A$973,144 Research and Development (R&D) Advance
06 Apr 2023 //
GLOBENEWSWIRE
Recce chooses CMAX for urinary tract infections therapy trial
20 Feb 2023 //
CLINICAL TRIALS ARENA
